



**IN-SILICO IDENTIFICATION OF NATURAL INHIBITORS OF HUMAN
TOPOISOMERASE AND KINASES TOWARDS TREATMENT OF VISCERAL
LEISHMANIASIS.**

MUHINDO JENIPHER

BU/UP/2017/ [1337]:

**A PROJECT REPORT SUBMITTED TO THE DEPARTMENT OF CHEMISTRY IN
PARTIAL FULFILMENT OF THE REQUIREMENTS FOR THE AWARD OF THE
DEGREE OF BACHELOR OF SCIENCE WITH EDUCATION OF BUSITEMA
UNIVERSITY.**

JANUARY, 2021

DECLARATION

I declare that this research project is my original work and has not been submitted elsewhere for examination, a ward of a degree or publication. Where other people's work or my own work has been used; this has properly been acknowledged and referenced in accordance with the Busitema University requirements.

Signature..... Date.....

MUHINDO JENIPHER

APPROVAL

This undergraduate research project report has been submitted for examination with my/our approval as research supervisor(s).

Signature..... Date.....

Dr. Andima Moses

Senior Lecturer

Department of chemistry

P.O Box 236, Tororo

mandima@sci.busitema.ac.ug

DEDICATION

I dedicate this research project to my father Mr.Bwambale Sostin and Forum for African Women Educationalists-Uganda Chapter (FAWE-U).

ACKNOWLEDGEMENT

First and foremost, I thank the Almighty God for continuously guiding me throughout this project and glory goes back to him.

I thank Forum for African Women Educationalist-Uganda chapter in partnership with MasterCard foundation for granting me the sponsorship to study at Busitema University.

I would like to extend my sincere appreciation to my supervisor Dr. Andima Moses for his parental efforts, guidance and words of encouragement that made me successfully complete this project. May the Almighty God bless you abundantly.

I extend great thanks to the entire chemistry department for the assistance during the process of my research work and may the Almighty God bless you abundantly.

I whole heartedly thank Dr.Masereka Abraham and Mr.Bwambale Sostin for always sacrificing their finances to support me throughout my studies and I pray that the Almighty God blesses you abundantly.

I would like to extend great thanks to my guardians Mr.Muthende Gideon, Mukonzo Mumbere and Aunt Muhindo Margret for their support and encouragement throughout my studies. I appreciate my mother Mrs. Grace Sostin, and grandmother Kyakimwa Mary for their words of encouragement and prayers.

I finally appreciate my friends Kalenda Tabitha, Derick Galimwifuba, and Kuteesa Sarah for their cooperation and team work.

TABLE OF CONTENTS

DECLARATION	2
APPROVAL	2
DEDICATION	3
ACKNOWLEDGEMENT	4
TABLE OF CONTENT	5
LIST OF FIGURES.....	7
LIST OF TABLES.....	7
ACROYNMS.....	8
ABSTRACT.....	9
CHAPTER ONE: INTRODUCTION.....	10
1.1 Background	10
1.2 Statement of the problem	10
1.3 Objectives.....	11
1.4 Justification	12
1.5 Scope	13
CHAPTER TWO: LITERATURE REVIEW.....	14
2.1 Leishmaniasis.....	14
2.2 Clinical syndromes of leishmaniasis.....	14
2.3 Epidemiology of leishmaniasis.....	15
2.4 Life cycle of leishmaniasis parasite.....	16
2.5 Risk factor of leishmaniasis.....	17

2.6	Control of leishmaniasis.....	18
2.7	Treatment of leishmaniasis.....	19
2.8	Molecular pathway of leishmaniasis.....	19
2.9	Computer aided drug design and anti-leishmanial drug.....	20
CHAPTER THREE: MATERIALS AND METHODS		21
3.1	Building compound library.....	21
3.2	Ligand preparation.....	21
3.3	Protein preparation.....	21
3.4	Docking method.....	21
CHAPTER FOUR: RESULTS AND DISCUSSIONS.....		22
4.1	Chemical library.....	22
4.2	Docking method validation.....	24
4.3	In-silico docking of compound library.....	25
4.4	Binding interactions.....	27
CHAPTER 5. CONCLUSION AND RECOMMENDATIONS.		31
5.1	Conclusion.....	31
5.2	Recommendations.	31
CHAPTER .6. REFERENCES AND APPENDICES.....		32
6.1	References	32-34

LIST OF FIGURES

Figure 1: life cycle of the leishmania parasite.....	Error! Bookmark not defined.
Figure 2. Apie chart showing compounds according to their genera.....	22
Figure 3: Binding ineractions of the best docked ligand for topoisomerase.....	27
Figure 4.prepared protein of topoisomerase.....	28
Figure.5. Binding interactions of best docked ligand for kinases.....	29
Figure 6: Prepared protein of kinases.....	30

LIST OF TABLES

No table of figures entries found.

ACRONYMS

VL: Visceral leishmaniasis

PKDL: Post kala azar dermal leishmaniasis

CL: Cutaneous leishmaniasis

MCL: Mucocutaneous leishmaniasis WHO: World Health Organization

CADD: computer aided drug design

GSK-3: Glycogen synthase kinase 3

6BIO: 6-bromoindirubin-30-oxime

LCDK1: leishmanial cyclin-dependent kinase-1

LGSK-3:leishmanial Glycogen synthase kinase 3

DNA: De-oxyribo nucleic acid.

WHO: World health organisation.

ADMET: Adsorption,distribution,metabolism,excretion and toxicity

MOE: molecular operating environment

PDB: protein data bank

ABSTRACT

Leishmaniasis is endemic in 98 countries and is closely associated with poverty more than a million new cases are reported per year and 350 million people are at the risk of contracting the infection. For the most severe form of leishmaniasis VL, approximately 300,000 new cases are estimated to occur annually resulting in approximately 40,000 deaths. Current treatment options against leishmaniasis are expensive and laden with serious side effects a longside wide spread

resistance by the parasite: In this study therefore, natural inhibitors of leishmanial topoisomerase and kinases were identified from a data base of natural products isolated from Ugandan medicinal plants using in silico docking experiments.

According to this research I found out that the best docked ligands are Grandibracteoside B and Grandibracteoside A with binding energies of -33.6003 Kcal/mol and -33.7991Kcal/mol respectively.so these compounds can be modified chemically and tested in-vitro for further research.

CHAPTER ONE: INTRODUCTION

1.1 Background

Leishmaniasis is a parasitic disease that presents four main clinical syndromes/forms: Cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), visceral Leishmaniasis/kalaazar (VL), and post kalaazar dermal leishmaniasis (PKDL). Visceral Leishmaniasis (VL) represents the most severe form of tropical disease and without proper diagnosis and treatment, is associated with high fatality [1]. Visceral leishmaniasis (VL), a chronic disease caused by parasites of the *Leishmania donovani* complex, is characterized by irregular fever, enlargement of the spleen, liver and weight loss.